Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Change in Receivables (2017 - 2025)

Historic Change in Receivables for Akebia Therapeutics (AKBA) over the last 9 years, with Q3 2025 value amounting to -$6.2 million.

  • Akebia Therapeutics' Change in Receivables fell 35613.31% to -$6.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $36.3 million, marking a year-over-year increase of 27913.97%. This contributed to the annual value of -$4.0 million for FY2024, which is 30704.23% down from last year.
  • Latest data reveals that Akebia Therapeutics reported Change in Receivables of -$6.2 million as of Q3 2025, which was down 35613.31% from $11.5 million recorded in Q2 2025.
  • In the past 5 years, Akebia Therapeutics' Change in Receivables registered a high of $27.9 million during Q1 2025, and its lowest value of -$58.7 million during Q3 2022.
  • In the last 5 years, Akebia Therapeutics' Change in Receivables had a median value of $3.1 million in 2024 and averaged $2.2 million.
  • Data for Akebia Therapeutics' Change in Receivables shows a peak YoY increase of 739956.14% (in 2022) and a maximum YoY decrease of 49995.23% (in 2022) over the last 5 years.
  • Akebia Therapeutics' Change in Receivables (Quarter) stood at $1.2 million in 2021, then soared by 1329.83% to $17.0 million in 2022, then dropped by 1.86% to $16.7 million in 2023, then crashed by 81.59% to $3.1 million in 2024, then plummeted by 300.39% to -$6.2 million in 2025.
  • Its last three reported values are -$6.2 million in Q3 2025, $11.5 million for Q2 2025, and $27.9 million during Q1 2025.